Srs Capital Advisors, Inc. Astria Therapeutics, Inc. Transaction History
Srs Capital Advisors, Inc.
- $1.5 Billion
- Q4 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 65 shares of ATXS stock, worth $402. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65Holding current value
$402% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ATXS
# of Institutions
115Shares Held
50.3MCall Options Held
75KPut Options Held
6.2K-
Perceptive Advisors LLC New York, NY6.49MShares$40.1 Million1.91% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$31.6 Million0.73% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$25.9 Million2.22% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$22 Million6.29% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$21.8 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $94M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...